Applied Therapeutics Inc · Q4 2020 earnings

Briefing

Reported financial results for the fourth quarter and full year ended December 31, 2020.

Applied Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2020, with a focus on advancing late-stage assets toward commercialization and initiating clinical development of new rare disease programs.

• AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA.
• Company is on track to submit NDA for AT-007 in Galactosemia no later than Q3 2021; Commercial preparations underway.
• ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy is on track to complete enrollment in mid-2021.
• Company is on track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021.

Headline financials

Revenue & EPS history

The company is focused on advancing its late-stage assets toward commercialization while initiating clinical development of its two new rare disease programs.